Antimicrobial susceptibility of clinical isolates of Stenotrophomonas maltophilia isolates from Europe, Asia, and Latin America (2018-2023).

• Tác giả: Mariana Castanheira, Timothy B Doyle, Rodrigo E Mendes, Helio S Sader, Marisa L Winkler
• Ngôn ngữ: eng
• Thông tin xuất bản: Canada : International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases , 2025
• Bộ sưu tập: NCBI
• ID: 191291

Tóm tắt

 BACKGROUND: The occurrence of Stenotrophomonas maltophilia infections, especially pneumonia, has increased consistently in the last years. We evaluated the antimicrobial susceptibility of a large collection of S. maltophilia collected in Europe, Asia, and Latin America. METHODS: Total 1287 clinical isolates were collected from 71 medical centres located in Western Europe (W-EU
  n = 682
  28 centres in 10 countries), Eastern Europe and Mediterranean region (E-EU
  n = 320
  18 centres in 11 countries), the Asia-Pacific region (APAC
  n = 182
  15 centres in 7 countries), and Latin America (LATAM
  n = 103
  10 centres in 7 countries). Most isolates were from patients with pneumonia (n = 790) and bloodstream infection (n = 234). Isolates were susceptibility tested by the CLSI broth microdilution method. RESULTS: Aztreonam-avibactam was the most active compound against isolates from all regions and infection types (MIC CONCLUSIONS: Aztreonam-avibactam may represent a valuable option to treat S. maltophilia infections, addressing a major unmet medical need.